Latest News and Press Releases

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim dataPositive outcome from AM-201 trial in prevention of antipsychotic-induced weight gainAddition of new intranasal...

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...

Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase...

Phase 1b trial with intranasal betahistine for prevention of antipsychotic-induced weight gain progressing towards final read-outPhase 2 trial with intranasal betahistine for treatment of acute...